A previous study has found that patients with estrogen receptor- positive/HER2- positive breast cancers may benefit more from drugs that disrupt the PI3K/AKT molecular pathway than patients with estrogen receptor- negative/HER2- positive breast cancers (37). This evidence concerns the gene ERBB2 and breast cancer.